Abstract Number: 314 • 2019 ACR/ARP Annual Meeting
Pre-treatment Screening for Hepatitis B and C Among Users of Biologics or New Synthetic Disease Modifying Drugs: An Analysis Using RISE Data
Background/Purpose: Testing for hepatitis B virus (HBV) and hepatitis C virus (HCV) is recommended for patients initiating biologics or new synthetic DMARDs, which can increase the risk…Abstract Number: 315 • 2019 ACR/ARP Annual Meeting
Improving the Rate of Tuberculosis Screening Among High Risk Rheumatoid Arthritis Patients on Biologic Agents Using a Proposed Questionnaire
Background/Purpose: The use of biologics has transformed the treatment paradigm for RA; however, reactivation of Mycobacterium Tuberculosis is still a concern. Frequent TB screenings without…Abstract Number: 316 • 2019 ACR/ARP Annual Meeting
Implementation of Cardiovascular Screening in Hispanic Patient Population with RA, SLE and PsA
Background/Purpose: Evidence suggests that the tools used for cardiovascular disease (CVD) risk assessment in the general population underestimate the true risk when they are applied…Abstract Number: 317 • 2019 ACR/ARP Annual Meeting
Improving Adherence to Pregnancy Screening in Patients on Teratogenic Medications Using an Electronic Medical Record Alert System: A Quality Improvement Initiative
Background/Purpose: Mycophenolate is widely prescribed in the rheumatology setting. However, usage of mycophenolate during the first trimester of pregnancy is associated with an increased risk…Abstract Number: 318 • 2019 ACR/ARP Annual Meeting
Improving Safe Prescribing of Hydroxychloroquine in a Safety Net Hospital Rheumatology Clinic
Background/Purpose: Hydroxychloroquine (HCQ) prescribing is standard of care for patients with SLE. The main potential side effect is retinal toxicity, especially at higher doses and…Abstract Number: 319 • 2019 ACR/ARP Annual Meeting
A Pragmatic Randomized Trial to Improve Safe Dosing of Hydroxychloroquine
Background/Purpose: Although generally well tolerated, the long-term use of hydroxychloroquine (HCQ) may lead to irreversible and potentially vision-threatening retinal toxicity. The American Academy of Ophthalmology…Abstract Number: 320 • 2019 ACR/ARP Annual Meeting
Hydroxychloroquine (HCQ) Prescribing Habits and Provider Opinion on Dosing Guidelines in the Rheumatology and Dermatology Practices of an Academic Institution
Background/Purpose: Research has shown potential retinal toxicity rates from HCQ as high as 7.5%. Research suggests toxicity is dose-related. In 2016, the American Academy of…Abstract Number: 321 • 2019 ACR/ARP Annual Meeting
Adherence to Weight-Based Dosing Guidelines in Patients Receiving Hydroxychloroquine for Rheumatoid Arthritis and Systemic Lupus Erythematosus
Background/Purpose: Hydroxychloroquine (HCQ) is a commonly prescribed medication for systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and other rheumatic diseases. However, HCQ may cause retinal…Abstract Number: 322 • 2019 ACR/ARP Annual Meeting
Hydroxychloroquine Retinal Screening and Dosing in an Unique Rheumatologic Patient Population
Background/Purpose: Hydroxychloroquine (HCQ) is used in many rheumatologic diseases. The American Academy of Ophthalmology (AAO) put forth guidelines in 2012 regarding retinal screening and dosing…Abstract Number: 323 • 2019 ACR/ARP Annual Meeting
Compliance with Hydroxychloroquine Dosage According to 2016 American Academy of Ophthalmology (AAO) Guidelines: A Study with 6591 Patients
Background/Purpose: Hydroxychloroquine (HCQ) induced retinal toxicity remains a major concern because it can lead to irreversible damage to retinal pigment epithelium and blindness. American Academy…Abstract Number: 324 • 2019 ACR/ARP Annual Meeting
Adherence to Guideline Directed Management of Gout Among VA Providers
Background/Purpose: Gout is the most common inflammatory arthritis, affecting about 4% of the adult population in the United States. Management is often costly, with estimates around…Abstract Number: 325 • 2019 ACR/ARP Annual Meeting
Frailty and Sarcopenia in Inflammatory Rheumatic Disease
Background/Purpose: Sarcopenia, the loss of skeletal muscle mass, is associated with adverse individual physical and metabolic changes contributing to morbidity and mortality. Sarcopenia is a…Abstract Number: 326 • 2019 ACR/ARP Annual Meeting
Cardiac Sarcoidosis Awareness: Are We Underdiagnosing?
Background/Purpose: Sarcoidosis, a multiorgan granulomatous disorder, may involve the heart at any time and often presents with cardiac conduction disturbances, heart failure, and sudden death.…Abstract Number: 327 • 2019 ACR/ARP Annual Meeting
Presentation Order Bias in Rheumatology Journals: A Content Analysis
Background/Purpose: Presentation order can influence the prominence of an academic article. Earlier-listed items or those at the top of tables of contents are more likely…Abstract Number: 328 • 2019 ACR/ARP Annual Meeting
Adverse Events During Colchicine Use: A Systematic Review and Meta-Analysis of Randomized Controlled Trial Events
Background/Purpose: Colchicine is a widely used drug used to treat rheumatic and inflammatory conditions. Due to its long historical use in medicine, controlled clinical trials…
ACR Meeting Abstracts